Wendoline Rojo-Contreras

Dr. Wendoline Rojo-Contreras

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2011 in Lupus
Verified
Journal Article
Closed access
WRW Rojo-Contreras
W Rojo-Contreras
EOEva Maria Olivas-Flores
Eva Maria Olivas-Flores
JGJi Gamez-Nava
Ji Gamez-Nava
HMH Montoya-Fuentes
H Montoya-Fuentes
BENJAMIN TRUJILLO-HERNANDEZBENJAMIN TRUJILLO-HERNANDEZ
BENJAMIN TRUJILLO-HERNANDEZ
LLLaura Gonzalez Lopez
Laura Gonzalez Lopez
Cervical human papillomavirus (HPV+) infection is associated with an increased risk of cervical dysplasia. Although the frequency of HPV+ in systemic lupus erythematosus (SLE) has been investigated in some races its prevalence in Hispanic women is still unknown. This cross-sectional study evaluated the prevalence of cervical HPV+ in Mexican women with SLE (n = 34) or rheumatoid arthritis (RA) (n = 43) and in healthy controls (n = 146). These women were interviewed about risk factors for sexually transmitted infections and cervical cytology analysis was performed. HPV+ viral types were identified using PCR: HPV+ was observed in 14.7% of SLE, 27.9% of RA and 30.8% of controls. High-risk HPV types were observed in 11.7% of women with SLE, 27.9% of women with RA, and in 26% of the controls. High-risk viral types 58, 35 and 18 were the most frequently identified in SLE. Two women with SLE had a high-grade squamous intraepithelial lesion and one had cervical cancer. An association was observed between methotrexate utilization, longer duration of therapy with prednisone, and HPV+ in RA or SLE. Thus, there is a high prevalence of cervical HPV infection in Mexican women with SLE or RA, and physicians must be vigilant in preventing the development of cervical dysplasia.

23 July 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
CACristina Artaza-Irigaray
Cristina Artaza-Irigaray
AMAndrea Molina-Pineda
Andrea Molina-Pineda
AAAdriana Aguilar-Lemarroy
Adriana Aguilar-Lemarroy
PLPablo C Ortiz Lazareno
Pablo C Ortiz Lazareno
LLLaura P. Limón-Toledo
Laura P. Limón-Toledo
Luis Felipe Jave-SuárezLuis Felipe Jave-Suárez
Luis Felipe Jave-Suárez
Keratinocyte infection with high-risk human papillomavirus genotypes has been linked to cancer development. In cervix, the alpha HPV16 and HPV18 have been reported as the mayor causative agents of cervical cancer. Oncogenic progression and chronic inflammation are closely related processes, with IL-6 as one of the main pro-inflammatory cytokines involved. However, there are limited studies about the regulation of IL-6 by low and high risk HPVs and the HPV proteins implicated in this modulation. In this work, we report the overexpression of IL-6 in HPV infected cervical cancer derived cell lines (HeLa and SiHa) compared to non-tumorigenic keratinocytes (HaCaT), and in Cervical Intraepithelial Neoplasia grade 1 HPV16 and HPV18 positive cervical samples compared to HPV negative samples without lesions. Moreover, we generated HaCaT keratinocytes that express E5, E6, and E7 from high risk (16 or 18) or low risk (62 and 84) HPVs. E5 proteins do not modify IL-6 expression, while E7 modestly increase it. Interestingly, E6 proteins in HaCaT cells upregulate IL-6 mRNA expression and protein secretion. Indeed, in HaCaT cells that express high risk HPV16E6 or HPV18E6 proteins, only the truncated E6* isoforms were expressed, showing the stronger IL-6 overexpression, while in HaCaT cells that express low risk HPV62 and HPV84 full length E6 proteins, IL-6 was also upregulated but not so drastically. Since HaCaT cells have a mutated p53 form that is not degraded by the introduction of E6 or E6/E7, it seems that E6/E7 regulate IL-6 by an additional mechanism independent of p53. In addition, basal keratinocytes showed a strong expression of IL-6R using immunohistochemistry, suggesting an autocrine mechanism over proliferative cells. Altogether, IL-6 cytokine expression in keratinocytes is upregulated by E6 and E7 proteins from HPVs 16, 18, 62, and 84, especially by high risk HPV16 and HPV18 E6*, which may contribute to promote a pro-inflammatory and highly proliferative microenvironment that can persist over time and lead to cervical tumorigenesis.

21 September 2022 in Healthcare
Verified
Journal Article
Open access
PDF file
WRWendoline Rojo-Contreras
Wendoline Rojo-Contreras
VDValeria Diaz-Rizo
Valeria Diaz-Rizo
XTXóchitl Trujillo
Xóchitl Trujillo
MHMiguel Huerta
Miguel Huerta
ARAlberto D. Rocha-Muñoz
Alberto D. Rocha-Muñoz
Mario Salazar ParamoMario Salazar Paramo
Mario Salazar Paramo
We estimate the prevalence and identified the associated factors of sexual dysfunction in Mexican women with rheumatoid arthritis (RA). A cross-sectional survey was applied to 100 women with RA and compared with 100 healthy, sexually active, adult women. Assessments included an interview using the Female Sexual Function Index (FSFI). Assessment of factors related to sexual dysfunction included gynecologic characteristics, disease activity (DAS-28), and functioning questionnaire (HAQ-DI). Mann-Whitney U test and the Chi-square test were used to compare medians and proportions between the groups. A multivariate logistic regression was performed using sexual dysfunction according to impairments shown by the FSFI. A higher proportion of RA patients had sexual dysfunction compared with controls. Domains with higher impairment in RA patients were desire, arousal, lubrication, and orgasm. A decrease in sexual function correlated with age (r = −0.365 p < 0.001) and higher scores in HAQ-DI (r = −0.261 p = 0.009). Those patients with a higher disability had higher impairments in desire, arousal, lubrication, and satisfaction. In the multivariate analysis, menopause was associated with sexual dysfunction (OR: 10.02; 95% CI: 1.05–95.40, p = 0.04), whereas use of methotrexate was a protective factor (OR: 0.32; 95% CI: 0.11–0.92, p = 0.03). Sexual dysfunction is highly prevalent in Mexican women with RA. Clinicians should systematically evaluate the impairment in sexual function in women with RA.

22 August 2008 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
LGLaura Gonzalez-Lopez
Laura Gonzalez-Lopez
JSJulia D. Sanchez-Hernandez
Julia D. Sanchez-Hernandez
EAErika A. G. Aguilar-Chavez
Erika A. G. Aguilar-Chavez
ACAdolfo R. Cota-Sanchez
Adolfo R. Cota-Sanchez
MLMaria A. Lopez-Olivo
Maria A. Lopez-Olivo
JGJorge I. Gamez-Nava
Jorge I. Gamez-Nava